Sugi Predict

Sugi Predict / Targets / HSD17B2

HSD17B2

17-beta-hydroxysteroid dehydrogenase type 2 · P37059 · HSD17B2 on Sugi Atlas →

90,598 patent compounds predicted against HSD17B2, 46,198 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL23418 SCHEMBL23418 1.00 20/20
SCHEMBL24752 SCHEMBL24752 1.00 20/20
SCHEMBL30683 SCHEMBL30683 1.00 20/20
SCHEMBL22550 SCHEMBL22550 0.88 20/20
SCHEMBL23522 SCHEMBL23522 0.84 20/20
SCHEMBL22633 SCHEMBL22633 0.77 20/20
SCHEMBL24083 SCHEMBL24083 0.76 20/20
SCHEMBL30843 SCHEMBL30843 0.75 20/20
SCHEMBL24271 SCHEMBL24271 0.70 20/20
SCHEMBL22549 SCHEMBL22549 0.70 20/20
SCHEMBL23202 SCHEMBL23202 0.70 20/20
SCHEMBL22396 SCHEMBL22396 0.69 20/20
SCHEMBL22642 SCHEMBL22642 0.69 20/20
SCHEMBL31261 SCHEMBL31261 0.68 20/20
SCHEMBL23498 SCHEMBL23498 0.67 20/20
SCHEMBL30294 SCHEMBL30294 0.67 20/20
SCHEMBL30910 SCHEMBL30910 0.67 20/20
SCHEMBL23813 SCHEMBL23813 0.64 20/20
SCHEMBL31404 SCHEMBL31404 0.53 20/20
SCHEMBL31477 SCHEMBL31477 0.53 20/20

Clinical trials — most relevant to HSD17B2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment PHASE4RECRUITING
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) PHASE3COMPLETED
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy PHASE3COMPLETED
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study PHASE3UNKNOWN
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia PHASE1/PHASE2COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old PHASE2ACTIVE_NOT_RECRUITING
AMG 386 and Abiraterone for Advanced Prostate Cancer PHASE2COMPLETED
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia PHASE2COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer PHASE1RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Linear Growth of Children With Congenital Adrenal Hyperplasia nanUNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
Final Height in Patients With CAH nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas nanUNKNOWN
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency. nanUNKNOWN
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
Fertility and Pregnancy in Patients With Classic Congenital Adrenal Hyperplasia nanCOMPLETED
Adrenal Function in GHD Children nanCOMPLETED
Hydrocortisone Modified-release in Adults: Real-world Monitoring of Longitudinal Outcomes in coNgenital Adrenal hYperplasia nanNOT_YET_RECRUITING
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HSD17B2 binder may also engage these)

ProteinNameSimilarity
Q62730 — 0.999 Q62730 →
F1QLP1 — 0.995 F1QLP1 →
O16881 — 0.995 O16881 →
P51658 — 0.992 P51658 →
Q80XN0 — 0.990 Q80XN0 →
P29147 — 0.989 P29147 →
Q5ZJZ5 — 0.987 Q5ZJZ5 →
Q02338 — 0.987 Q02338 →
P0DKC6 — 0.986 P0DKC6 →
P0DKC5 — 0.986 P0DKC5 →
Q02337 — 0.985 Q02337 →
Q10130 — 0.985 Q10130 →
Q6QLL4 — 0.985 Q6QLL4 →
Q08651 — 0.984 Q08651 →
F4JJR8 — 0.984 F4JJR8 →
A5PJF6 — 0.984 A5PJF6 →
P0DY82 — 0.984 P0DY82 →
Q6GQ37 — 0.984 Q6GQ37 →
F4IDQ6 — 0.983 F4IDQ6 →
Q7T2D1 — 0.983 Q7T2D1 →
Q3V1F8 — 0.983 Q3V1F8 →
Q8LKV5 — 0.983 Q8LKV5 →
A7LB59 — 0.983 A7LB59 →
Q8BTX9 — 0.983 Q8BTX9 →
Q22943 — 0.982 Q22943 →
P56523 — 0.982 P56523 →
G5EDL5 — 0.982 G5EDL5 →
Q0IIS3 — 0.982 Q0IIS3 →
Q80ZF7 — 0.982 Q80ZF7 →
Q4V8B7 — 0.982 Q4V8B7 →